Insights and thought leadership from Cambrianites

Our Senior Ventures Director, Ethan Sarnoski, PhD., outlines his hypothesis-driven approach for evaluating the quality of any given therapeutics program as one component of the larger drivers of success for a company.

Our VP of Global Policy and Strategic Initiatives, Adrienne Hallett explores the vast potential impact of ATX-304, a drug being developed by our PipeCo Amplifier Therapeutics. ATX-304 is a peripherally restricted pan-AMPK activator with the potential to aid in weight loss and maybe even improve cardiac health by increasing metabolism.

Our CEO James Peyer highlights ATX-304, the drug being developed by our PipeCo Amplifier Therapeutics. ATX-304 might be able to help people lose weight and maybe even increase cardiac health by increasing metabolism.

Dennis Yamashita, PhD, our former EVP of Chemistry and Chair of the Board of our PipeCo, Tornado Therapeutics, shares his first-hand witness of the evolution of Rapamycin; it was discovered on Easter Island and has evolved into a vital immunosuppressant and cancer treatment through its chemical relatives, rapalogs. The science is promising for new applications, such as treating and preventing diseases of aging.

CEO James Peyer and Vice President of Global Policy and Strategic Initiatives, Adrienne Hallett visit DC to meet with elected officials and administration experts, advocates and think tanks about the medicines Cambrian is developing and the challenges inherent in developing preventive medicines.

Our VP of Global Policy and Strategic Initiatives, Adrienne Hallett introduces our latest blog segment "An Ounce of Longevity" where she will explore the policy implications of healthy longevity medicines. In her first segment, she shares what healthy aging means to her and highlights the implications for families, communities, societies, and economies.

Our former EVP of Drug Discovery, Georg C. Terstappen, shares how his passion drove him to embark on what became a 30-year journey through the biopharmaceutical industry, and why he has chosen to continue his journey with Cambrian. He also highlights the remarkable progress of Isterian, one of our PipeCo’s that he heads, and its promising lead-stage TG2 inhibitor which offers a compelling path forward for IPF.

Our CEO James Peyer, emphasizes the importance of changes in the Extracellular Matrix (ECM) as a significant but often overlooked aspect of aging. He reveals our latest PipeCo, Isterian Biotech, which is focused on developing novel drugs to remove excess pathological protein crosslinks from fibrotic organs for the treatment of fibrosis, and to extend healthy lifespan.

Our CEO James Peyer highlights the recent surge of interest and investments in the field of longevity biotech, particularly in relation to moonshot technologies. We, as a company, primarily focus on innovative therapies while also exploring a few longer-term moonshots as we understand the importance of establishing longevity innovations through approved drugs for simpler regulatory pathways, and once successful, they can serve as precedents for more complex moonshot technologies.

Our CEO James Peyer addresses the challenges of multi-disease prevention trials and the lack of biomarkers for cost-effective prevention trials. He then reveals our three-stage "Secret Master Plan" which will allow us to overcome these obstacles and realize our mission to revolutionize medicine and extend human healthspan by preventing age-related decline.